Jordi Bruix1 , 2

Hepatology · 2001–2021

A researcher in the Science corpus: 32 papers; trusts 14 researchers and is trusted by 46 researchers here, as inferred from the citation graph.

Subfields

• Hepatology — 379 citations into it; #2 of 151 by trust here, #2 by citations
• Epidemiology — 223 citations into it; #162 of 2,148 by trust here, #112 by citations
• Oncology — 148 citations into it
• Surgery — 147 citations into it; #1,075 of 1,106 by trust here, #90 by citations
• Pathology and Forensic Medicine — 46 citations into it; #31 of 414 by trust here, #45 by citations
• Radiology, Nuclear Medicine and Imaging — 18 citations into it

Whom Jordi Bruix1 , 2 trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. J. Llovet
2. Riccardo Lencioni
3. M. Sherman
4. R. Poon
5. A. Cheng
6. C. Lo
7. V. Mazzaferro
8. S. Fan
9. Alejandro Forner1 , 2
10. M. Kudo

Who trusts Jordi Bruix1 , 2 overall

1. J. Llovet
2. Riccardo Lencioni
3. Amit G. Singal
4. L. Kulik
5. R. Salem
6. J. Heimbach
7. Alejandro Forner1 , 2
8. Peter R. Galle
9. María E. Reig1 , 2
10. M. Sherman

Papers from Jordi Bruix1 , 2's perspective

Ordered by how strongly the researchers Jordi Bruix1 , 2 trusts endorse each paper. Same corpus, a different order for every researcher.

1. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. (Gastroenterology)
2. Novel advancements in the management of hepatocellular carcinoma in 2008. (Journal of Hepatology)
3. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. (Gastroenterology)
4. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. (The Lancet Oncology)
5. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. (American Journal of Epidemiology)
6. Portal Vein Embolization Before Right Hepatectomy: Prospective Clinical Trial (Annals of Surgery)
7. Molecular Targeted Therapies in Hepatocellular Carcinoma (Hepatology)
8. Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection. (Journal of the American College of Surgeons)
9. The natural history of compensated cirrhosis due to hepatitis C virus: A 17‐year cohort study of 214 patients (Hepatology)
10. INCIDENCE OF HEPATOCELLULAR CARCINOMA AND ASSOCIATED RISK FACTORS IN HEPATITIS C-RELATED ADVANCED LIVER DISEASE (Gastroenterology)

Their papers

• Pivotal role of mTOR signaling in hepatocellular carcinoma. (2008) — 725 citations
• Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma (2008) — 1,244 citations
• Focal Gains of Vascular Endothelial Growth Factor A and Molecular Classification of Hepatocellular Carcinoma (2008) — 647 citations
• BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update. (2021) — 2,982 citations
• Cholangiocarcinoma 2020: the next horizon in mechanisms and management (2020) — 2,046 citations
• Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. (2017) — 3,215 citations
• Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. (2016) — 1,557 citations
• Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial. (2016) — 660 citations
• Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. (2016) — 967 citations
• Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. (2015) — 937 citations
• Hepatocellular carcinoma: clinical frontiers and perspectives (2014) — 1,329 citations
• EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. (2012) — 3,548 citations
• Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial , (2012) — 790 citations
• Hepatocellular carcinoma (2012) — 830 citations
• Management of hepatocellular carcinoma: An update (2011) — 8,421 citations
• Current Strategy for Staging and Treatment: The BCLC Update and Future Prospects (2010) — 1,091 citations
• Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. (2009) — 1,897 citations
• Novel advancements in the management of hepatocellular carcinoma in 2008. (2008) — 866 citations
• Sorafenib in advanced hepatocellular carcinoma. (2008) — 6,212 citations
• Design and endpoints of clinical trials in hepatocellular carcinoma. (2008) — 1,196 citations